Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population

Cancer Genetics and Cytogenetics

Volumn 190, Issue 2, 2009, Pages 101-107

  Rouissi, Kamel ^a   Ouerhani, Slah ^a   Marrakchi, Raja ^a   Ben Slama, Mohamed R ^b   Sfaxi, Mohamed ^b   Ayed, Mohsen ^b   Chebil, Mohamed ^b   El Gaaied, Amel Benammar ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE 2; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUNISIA;

AGED; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; POLYMORPHISM, GENETIC; SMOKING; TUNISIA; URINARY BLADDER NEOPLASMS;

NICOTIANA TABACUM;

EID: 64549084067     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.01.007     Document Type: Article

References (43)

1. Cohen S.M., and Johansson S.L. Epidemiology and etiology of bladder cancer. Urol Clin North Am 19 (1992) 421-428
2. Raunio H., Husgafvel-Pursiainen K., Anttila S., Hietanen E., Hirvonen A., and Pelkonen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility: a review. Gene 159 (1995) 113-121
3. Kaprio J. Genetic epidemiology. B Med J 320 (2000) 1257-1259
4. Hayes J.D., Flanagan J.U., and Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 45 (2005) 51-88
5. Sheehan D., Meade G., Foley V.M., and Dowd C.A. Structure, function and evolution of glutathione transferases: implications for classification of non mammalian members of an ancient enzyme superfamily. Biochem J 360 (2001) 1-16
6. Ouerhani S., Tebourski F., Ben Slama M.R., Marrakchi R., Rabeh M., Ben Hessine L., Ayed M., and Ben Ammar El Gaaied A. The role of glutathione transferases M1 and T1 in individual susceptibility to bladder cancer in a Tunisian population. Ann Human Biol 33 (2006) 529-535
7. Rebbeck T.R., Walker A.H., Jaffe J.M., White D.L., Wein A.J., and Malcowiez S.B. Glutathione S-transferases μ (GSTM1) and θ (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomark Prev 8 (1999) 283-287
8. Lin H.J., Han C.Y., Bernstein D.A., Hsiao W., Lin B.K., and Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 15 (1994) 1077-1081
9. Ford J.G., Li Y., O'Sullivan M.M., Demopoulos R., Garte S., Taioli E., and Branott-Rauf P.W. Glutathione S-transferase M1 polymorphism and lung cancer risk in African-Americans. Carcinogenesis 21 (2000) 1971-1975
10. Karagas M.R., Park S., Warren A., Hamilton J., Nelson H.H., Mott L.A., and Kelsey K.T. Gender, smoking, glutathione- S-transferase variants and bladder cancer incidence: A population-based study. Cancer Lett 219 (2005) 63-69
11. Garte S., Gaspari L., Alexandrie A.K., Ambrosone C., Autrup H., Autrup J.L., Baranova H., Bathum L., Benhamou S., and Boffetta P. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10 (2001) 1239-1248
12. Abdel-Rahman S.Z., Anwar W.A., Abdel-Ala W.E., Mostafa H.M., and Au W.W. GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Cancer Detect Prev 22 (1998) 129-138
13. Salagovic J., Kalina I., Stubna J., Habalova V., Hrivnak M., Valansky L., Kohut A., and Biros E. Genetic polymorphism of glutathione S-transferase M1 and T1 as a risk factor in lung and bladder cancers. Neoplasma 45 (1998) 312-317
14. Hengstler J.G., Kett A., Arand M., Oesch-Bartlomowicz B., Oesch F., Pilch H., and Tanner B. Glutathione S-transferase T1 and M1 gene defects in ovarian carcinoma. Cancer Lett 130 (1998) 43-48
15. Katoh T., Inatomi H., Kim H., Yang M., Matsumoto M., and Kawatomo T. Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. Cancer Lett 132 (1998) 147-152
16. Badawi A.F., Hirvonen A., Bell D.A., Lang N.P., and Kadlubar F.F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adducts formation in human urinary bladder. Cancer Res 55 (1995) 5230-5237
17. Kloth M.T., Gee R.L., Messing E.M., and Swaminathan S. Expression of N acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis 15 (1994) 2781-2787
18. Blum M., Grant D.M., McBride W., Heim M., and Meyer U.A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 9 (1990) 193-203
19. Hein D.W. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25 (2006) 1649-1658
20. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., Devanaboyina U.S., Nangju N.A., and Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9 (2000) 29-42
21. Brockmöller J., Cascorbi I., Kerb R., and Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56 (1996) 3915-3925
22. Risch A,Wallace D.M.A., Bathers S., and Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4 (1995) 231-236
23. Probst-Hensch N.M., Bell D.A., Watson M.A., Skipper P.L., Tannenbaum S.R., Chan K.K., Ross R.K., and Yu M.C. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev 9 (2000) 619-623
24. Vineis P., Bartsch H., Caporaso N., Harrington A.M., Kadlubar F.F., Landi M.T., Malaveille C., Shields P.G., Skipper P., and Talaska G. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369 (1994) 154-156
25. Yu M.C., Skipper P.L., Taghizadeh K., Tannenbaum S.R., Chan K.K., Henderson B.E., and Ross R.K. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Nat Cancer Inst 86 (1994) 712-716
26. Airoldi L., Orsi F., Magagnotti C., Coda R., Randone D., Casetta G., Peluso M., Hautefeuille A., Malaveille C., and Vineis P. Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies. Carcinogenesis 23 (2002) 861-866
27. Hao G.Y., Zhang W.D., Chen Y.H., Zhang D.X., and Zhang Y.H. Relationship between genetic polymorphism of NAT2 and susceptibility to urinary bladder cancer. Zhonghua Zhong Liu Za Zhi 26 (2004) 283-286
28. Sellami A., Jlidi R., Hsaïri M., and Achour N. Registre du cancer du Sud Tunisie 1997. Hôpital Habib Bourguiba 2 (2000) 32-35
29. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual. 2nd edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
30. Arand M., Muhlbaur R., Hengstler J., Jäger E., Fuchs J., Winkler L., and Oesch F. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 236 (1996) 384-386
31. Hsieh F.I., Pu Y.S., Chern H.D., Hsu L.I., Chiou H.Y., and Chen C.J. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br J Cancer 81 (1999) 537-541
32. Fukino K., Sasaki Y., Hirai S., Nakamura T., Hashimoto M., Yamagishi F., and Ueno K. Effect of N-acetyltransferase 2(NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum Concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 33 (2008) 187-195
33. Vastis K.P., Weber W.W., Bell D.A., Dupret J.M., Evans D.A.P., Grant D.M., Hem D.W., Lin H.J., Meyer U.A., Rellin M.V., Sim E., Suzuki T., and Yamazoc Y. Nomenclature for N-acetyltransferases. Pharmacogenetics 5 (1995) 1-17
34. O'Gorman T.W., and Woolson R.F. The effect of category choice on the odds ratio and several measures of association in case-control studies. Commun Stat 22 (1993) 1157-1171
35. Garcia-Closas M., Malats N., Silverman D., Dosemeci M., Kogevinas M., Hein D.W., Tardon A., Serra C., Carrato A., Garcia-Closas R., Lloreta J., Castano-Vinyals G., Yeager M., Welch R., Chanock S., Chatterjee N., Wacholder S., Samanic C., Tora M., Fernandez F., Real F.X., and Rothman N. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366 (2005) 649-659
36. Kempkes M., Golka K., Reich S., Reckwitz T., and Bolt H.M. Glutathione transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71 (1996) 123-126
37. Lee S.J., Cho S.H., Park S.K., Kim S.W., Park M.S., Choi H.Y., Choi J.Y., Lee S.Y., Im H.J., Kim J.Y., Yoon K.J., Choi H., Shin S.G., Park T.W., Rothman N., Hirvonen A., and Kang D. Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. Cancer Lett 177 (2002) 173-179
38. Kim W.J., Kim H., Kim C.H., Lee M.S., Oh B.R., Lee H.M., and Katoh T. GSTT1-null genotype is a protective factor against bladder cancer. Urology 60 (2002) 913-918
39. Khedhaier A., Hassen E., Bouaouina N., Gabbouj S., Ben Ahmed S., and Chouchane L. Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer 8 (2008) 109-121
40. Bell D.A., Taylor J.A., Butler M.A., Stephens E., Wiest J., Brubaker L., Kadlubar F.F., and Lucier G.W. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. carcinogenesis 14 (1993) 1689-1692
41. El Desoky E.S., Abdel Salam Y.M., Salama R.H., El Akkad M.A., Atanasova S., von Ahsen N., Armstrong V.W., and Oellerich M. NAT2*5/*5 genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians. Ther Drug Monit 27 (2005) 297-304
42. Fretland A.J., Doll M.A., Leff M.A., and Hein D.W. Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics 11 (2001) 511-520
43. Zang Y., Zhao S., Doll M.A., States J.C., and Hein D.W. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 14 (2004) 717-723